Novo Nordisk ramps up semaglutide defence as generics lurk

The Danish pharma giant is expanding its patent defence in India as multiple generics prepare to challenge its blockbuster diabetes and weight-loss drug ahead of 2026 patent expiry.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

Novo Nordisk India strategy suffers semaglutide patent setback

4 December 2025 The Delhi High Court has denied an injunction against an Indian generic manufacturer, finding credible challenges to the validity of Novo's semaglutide patent—flagging concerns over obviousness, double patenting, and evergreening.

Americas

Pfizer beats Novo Nordisk in $10bn bidding war

13 November 2025 US Federal Trade Commission’s antitrust warning tipped the scales in Pfizer’s favour, ending a heated dispute over a weight-loss biotech.

Americas

Novo Nordisk files fresh lawsuits to intercept Wegovy generics

11 September 2024 Danish multinational asks Delaware court to block semaglutide generics from Sun Pharma and Mylan | ANDAs infringe two claims of patent granted in July, Novo claims.

More features

Cooley drafts in 30-strong life sciences team from rival

US govt backs Hikma over ‘skinny label’ rules

Marks & Clerk adds multi-jurisdictional disputes expert

USPTO issues guidance to support patent eligibility declarations

Chest-worn heart monitor tech flatlines in US patent appeal

Novo Nordisk India strategy suffers semaglutide patent setback

FedCirc voids Seagen patent in $41m cancer treatment dispute

Blank Rome expands team with Chicago partner

Novo Nordisk ramps up semaglutide defence as generics lurk

More on this story

Editor's picks

Editor's picks

More features